Semaglutide and cardiovascular risk in type 1 diabetes: A predictive modelling analysis in a double-blind, randomised, placebo-controlled cross-over trial.

Diabetes Obes Metab · 2026 · PMC12992154 · PMID 41623193

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a possible trendno p-value reported

The modest risk reductions observed with the ST1RE model, however, suggest a possible trend toward long‐term cardiovascular benefit.

also in 939 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.